GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Absci Corp (NAS:ABSI) » Definitions » Return-on-Tangible-Equity

Absci (ABSI) Return-on-Tangible-Equity : -54.83% (As of Mar. 2024)


View and export this data going back to 2021. Start your Free Trial

What is Absci Return-on-Tangible-Equity?

Return-on-Tangible-Equity is calculated as Net Income divided by its average total shareholder tangible equity. Total shareholder tangible equity equals to Total Stockholders Equity minus Intangible Assets. Absci's annualized net income for the quarter that ended in Mar. 2024 was $-87.90 Mil. Absci's average shareholder tangible equity for the quarter that ended in Mar. 2024 was $160.31 Mil. Therefore, Absci's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 was -54.83%.

The historical rank and industry rank for Absci's Return-on-Tangible-Equity or its related term are showing as below:

ABSI' s Return-on-Tangible-Equity Range Over the Past 10 Years
Min: -100.78   Med: -67.14   Max: -42.71
Current: -66.96

During the past 5 years, Absci's highest Return-on-Tangible-Equity was -42.71%. The lowest was -100.78%. And the median was -67.14%.

ABSI's Return-on-Tangible-Equity is ranked worse than
60.49% of 1306 companies
in the Biotechnology industry
Industry Median: -46.86 vs ABSI: -66.96

Absci Return-on-Tangible-Equity Historical Data

The historical data trend for Absci's Return-on-Tangible-Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Absci Return-on-Tangible-Equity Chart

Absci Annual Data
Trend Dec19 Dec20 Dec21 Dec22 Dec23
Return-on-Tangible-Equity
- - -100.78 -42.71 -67.14

Absci Quarterly Data
Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
Return-on-Tangible-Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -48.74 -95.99 -56.25 -68.43 -54.83

Competitive Comparison of Absci's Return-on-Tangible-Equity

For the Biotechnology subindustry, Absci's Return-on-Tangible-Equity, along with its competitors' market caps and Return-on-Tangible-Equity data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Absci's Return-on-Tangible-Equity Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Absci's Return-on-Tangible-Equity distribution charts can be found below:

* The bar in red indicates where Absci's Return-on-Tangible-Equity falls into.



Absci Return-on-Tangible-Equity Calculation

Absci's annualized Return-on-Tangible-Equity for the fiscal year that ended in Dec. 2023 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets )/ count )
(A: Dec. 2023 )  (A: Dec. 2022 )(A: Dec. 2023 )
=-110.566/( (201.457+127.923 )/ 2 )
=-110.566/164.69
=-67.14 %

Absci's annualized Return-on-Tangible-Equity for the quarter that ended in Mar. 2024 is calculated as

Return-on-Tangible-Equity=Net Income/( (Total Tangible Equity+Total Tangible Equity)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=Net Income/( (Total Stockholders Equity - Intangible Assets+Total Stockholders Equity - Intangible Assets)/ count )
(Q: Mar. 2024 )  (Q: Dec. 2023 )(Q: Mar. 2024 )
=-87.9/( (127.923+192.696)/ 2 )
=-87.9/160.3095
=-54.83 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual Return-on-Tangible-Equity, the net income of the last fiscal year and the average total shareholder tangible equity over the fiscal year are used. In calculating the quarterly data, the net income data used here is four times the quarterly (Mar. 2024) net income data. Return-on-Tangible-Equity is displayed in the 10-year financial page.


Absci  (NAS:ABSI) Return-on-Tangible-Equity Explanation

Return-on-Tangible-Equity measures the rate of return on the ownership interest (shareholder's tangible equity) of the common stock owners. It measures a firm's efficiency at generating profits from every unit of shareholders' tangible equity (shareholders equity minus intangibles). Return-on-Tangible-Equity shows how well a company uses investment funds to generate earnings growth. Return-on-Tangible-Equitys between 15% and 20% are considered desirable.


Be Aware

Net Income is used.

Because a company can increase its Return-on-Tangible-Equity by having more financial leverage, it is important to watch the leverage ratio when investing in high Return-on-Tangible-Equity companies. Like Return-on-Tangible-Asset, Return-on-Tangible-Equity is calculated with only 12 months data. Fluctuations in company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective.

Asset light businesses require very few assets to generate very high earnings. Their Return-on-Tangible-Equitys can be extremely high.


Absci Return-on-Tangible-Equity Related Terms

Thank you for viewing the detailed overview of Absci's Return-on-Tangible-Equity provided by GuruFocus.com. Please click on the following links to see related term pages.


Absci (ABSI) Business Description

Industry
Traded in Other Exchanges
N/A
Address
18105 SE Mill Plain Boulevard, Vancouver, WA, USA, 98683
Absci Corp is the Artificial intelligence powered synthetic biology company unlocking the potential of proteins as the next generation of therapeutics. It enables the creation of novel biologics by unifying biologic drug discovery and cell line development into one simultaneous process.
Executives
Frans Van Houten director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Daniel A Rabinovitsj director 400 W CESAR CHAVEZ, AUSTIN TX 78701
Andreas Busch director C/O CYCLERION THERAPEUTICS, INC., 301 BINNEY STREET, CAMBRIDGE MA 02142
Sarah Korman officer: General Counsel 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98660
Todd Bedrick officer: VP, CCPAO 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Joseph Sirosh director C/O COMPASS, INC., 155 AVENUE OF THE AMERICAS, SIXTH FLOOR, NEW YORK NY 10013
Sean Mcclain director, 10 percent owner, officer: President and Chief Executive 18105 SE MILL PLAIN BLVD, SUITE 350, VANCOUVER WA 98683
Zachariah Jonasson director 18105 SE MILL PLAIN BLVD, VANCOUVER WA 98683
Eli Casdin director, 10 percent owner 1350 AVENUE OF THE AMERICAS, SUITE 1140, NEW YORK NY 10019
Casdin Partners Master Fund, L.p. director, 10 percent owner WALKER HOUSE, 87 MARY STREET, GEORGE TOWN E9 KY1-9001
Redmile Group, Llc director, 10 percent owner ONE LETTERMAN DRIVE, BUILDING D, SUITE D3-300, SAN FRANCISCO CA 94129
Karen K Mcginnis director INSIGHT ENTERPRISES INC, 1305 WEST AUTO DRIVE, TEMPE AZ 85284
Redmile Biopharma Investments Ii, L.p. director, 10 percent owner LETTERMAN DIGITAL ARTS CENTER, ONE LETTERMAN DRIVE, SUITE D3-300, SAN FRANCISCO CA 94129
Phoenix General Partner Ii Llc 10 percent owner 1700 S. EL CAMINO REAL, SUITE 335, SAN MATEO CA 94402
Nikhil Goel officer: Chief Business Officer 101 E. 6TH STREET, SUITE 350, VANCOUVER WA 98660